Natixis’s Astria Therapeutics ATXS Stock Holding History

Natixis’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-70,000	Closed	-$916K	–	1118
2025 Q4	$916K	Buy	+70,000	New	+$836K	﹤0.01%	737

Natixis's ATXS Position: Q1 2026 in Review

Natixis sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 70,000 shares — an estimated $916K sold.

Natixis first reported a position in ATXS in Q4 2025 and held it in 1 quarter. The position peaked at $916K in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Natixis reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Natixis sold 70,000 Astria Therapeutics shares in Q1 2026, an estimated $916K.
Natixis first reported a position in Astria Therapeutics in Q4 2025 and held it in 1 quarter.
Natixis's Astria Therapeutics position peaked at $916K in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.